OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
What research <strong>and</strong> development (R&D) strategies will companies leverage <strong>to</strong> compete in<br />
the future <strong>RSV</strong> marketplace?<br />
Which patient population(s) are most likely <strong>to</strong> be targeted by novel <strong>RSV</strong> prophylactic <strong>and</strong><br />
therapeutic agents?<br />
What clinical <strong>and</strong> commercial fac<strong>to</strong>rs are likely <strong>to</strong> influence <strong>RSV</strong> product uptake in the<br />
7MM?<br />
Key Findings<br />
The global <strong>RSV</strong> marketplace which, for the purposes of this report, encompasses the<br />
sales of products for the prevention or treatment of <strong>RSV</strong> in the 7MM was worth<br />
approximately $640m in 2014. GlobalData projects the market <strong>to</strong> surpass $2.3bn in sales by<br />
<strong>2024</strong>, at a compound annual growth rate (CAGR) of 29.9% from 2014<strong>2024</strong>. The sales are<br />
projected <strong>to</strong> originate predominantly from the US (a 62% market share), followed distantly<br />
by the 5EU (a 29% market share).<br />
The anticipated arrival of novel prophylactic mAbs that boast improved dosing criteria<br />
compared with Synagis, led by MedImmunes MEDI8897, will be a principal driver of <strong>RSV</strong><br />
market growth across the 7MM. The licensure of the first adult vaccine <strong>to</strong> offer protection<br />
against <strong>RSV</strong>, Novavaxs <strong>RSV</strong>F Vaccine, will also stimulate rapid growth in a previously<br />
untapped segment of the marketplace.<br />
A persistent lack of patient <strong>and</strong> physician awareness of <strong>RSV</strong> in adult patients specifically<br />
the infections substantial impact on morbidity <strong>and</strong> mortality in the elderly will serve as a<br />
key impediment <strong>to</strong> market growth from 2014<strong>2024</strong>.<br />
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz<br />
Scope<br />
Overview of <strong>RSV</strong> infections, including epidemiology, etiology, pathophysiology,<br />
symp<strong>to</strong>ms, diagnosis, <strong>and</strong> current management strategies.<br />
Topline <strong>RSV</strong> market revenue from 2014<strong>2024</strong>. Annual cost of therapy (ACOT) <strong>and</strong> major<br />
pipeline product sales in this forecast period are included.<br />
Key <strong>to</strong>pics covered include current treatment options, unmet needs <strong>and</strong> opportunities, <strong>and</strong><br />
the drivers <strong>and</strong> barriers affecting <strong>RSV</strong> product sales in the 7MM.<br />
Pipeline analysis: comprehensive data split across different phases, emerging novel trends<br />
under development, synopses of innovative earlystage projects, <strong>and</strong> detailed analysis of<br />
latestage pipeline products.<br />
<strong>Analysis</strong> of the current <strong>and</strong> future market competition in the global <strong>RSV</strong> market. Insightful<br />
review of the key industry drivers, restraints <strong>and</strong> challenges. Each trend is independently<br />
researched <strong>to</strong> provide qualitative analysis of its implications.<br />
Reasons <strong>to</strong> buy<br />
The report will enable you <strong>to</strong> <br />
Develop <strong>and</strong> design your inlicensing <strong>and</strong> outlicensing strategies through a review of<br />
pipeline products <strong>and</strong> technologies, <strong>and</strong> by identifying the companies with the most robust<br />
pipeline.<br />
Develop business strategies by underst<strong>and</strong>ing the trends shaping <strong>and</strong> driving the global<br />
<strong>RSV</strong> market.
Change language